138 related articles for article (PubMed ID: 30805927)
21. Mediator Complex Subunit 19 Promotes the Development of Hepatocellular Carcinoma by Regulating the AKT/mTOR Signaling Pathway.
Zhang Y; Qin P; Xu X; Li M; Huang H; Yan J; Zhou Y
Front Oncol; 2021; 11():792285. PubMed ID: 35047403
[TBL] [Abstract][Full Text] [Related]
22. Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway.
Wang G; Zhang X; Zhou Z; Song C; Jin W; Zhang H; Wu W; Yi Y; Cui H; Zhang P; Liu X; Xu W; Shen X; Shen W; Wang X
Discov Oncol; 2023 Jan; 14(1):4. PubMed ID: 36631680
[TBL] [Abstract][Full Text] [Related]
23. ADORA1 Promotes Hepatocellular Carcinoma Progression via PI3K/AKT Pathway.
Ni S; Wei Q; Yang L
Onco Targets Ther; 2020; 13():12409-12419. PubMed ID: 33293832
[TBL] [Abstract][Full Text] [Related]
24. DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis.
Wu Y; Xu X; Liu M; Qin X; Wu Q; Ding H; Zhao Q
Biochem Pharmacol; 2022 Jul; 201():115093. PubMed ID: 35580648
[TBL] [Abstract][Full Text] [Related]
25. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of BZW2 expression in lung adenocarcinoma patients.
Wang S; Bai W; Huang J; Lv F; Bai H
Int J Clin Exp Pathol; 2019; 12(12):4289-4296. PubMed ID: 31933829
[TBL] [Abstract][Full Text] [Related]
27. DHW-208, A Novel Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Has Anti-Hepatocellular Carcinoma Activity Through Promoting Apoptosis and Inhibiting Angiogenesis.
Wang S; Wu Y; Liu M; Zhao Q; Jian L
Front Oncol; 2022; 12():955729. PubMed ID: 35903690
[TBL] [Abstract][Full Text] [Related]
28. PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling.
Jiang H; Zhou Z; Jin S; Xu K; Zhang H; Xu J; Sun Q; Wang J; Xu J
Cancer Sci; 2018 May; 109(5):1414-1427. PubMed ID: 29603830
[TBL] [Abstract][Full Text] [Related]
29. Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation.
Wen S; Liu Y; Yang M; Yang K; Huang J; Feng D
Oncol Rep; 2016 Oct; 36(4):2193-9. PubMed ID: 27509921
[TBL] [Abstract][Full Text] [Related]
30. Leucine zipper downregulated in cancer 1 may serve as a favorable prognostic biomarker by influencing proliferation, colony formation, cell cycle, apoptosis, and migration ability in hepatocellular carcinoma.
Chen H; Chen S; Chen C; Li A; Wei Z
Front Genet; 2022; 13():900951. PubMed ID: 35957693
[No Abstract] [Full Text] [Related]
31. miR-3651 Participates in the Growth Cycle of Hepatocellular Carcinoma Cells and Promotes the Malignant Metastasis via the PI3K/AKT/mTOR Signalling Pathway.
Liu Y; Hu L; Liu Q; Ye J; Zhang J
J Oncol; 2022; 2022():5744999. PubMed ID: 36245984
[TBL] [Abstract][Full Text] [Related]
32. Short hairpin RNA-mediated knockdown of nuclear factor erythroid 2-like 3 exhibits tumor-suppressing effects in hepatocellular carcinoma cells.
Yu MM; Feng YH; Zheng L; Zhang J; Luo GH
World J Gastroenterol; 2019 Mar; 25(10):1210-1223. PubMed ID: 30886504
[TBL] [Abstract][Full Text] [Related]
33. Long non-coding RNA LINC00473 acts as a microRNA-29a-3p sponge to promote hepatocellular carcinoma development by activating Robo1-dependent PI3K/AKT/mTOR signaling pathway.
Song Q; Zhang H; He J; Kong H; Tao R; Huang Y; Yu H; Zhang Z; Huang Z; Wei L; Liu C; Wang L; Ning Q; Huang J
Ther Adv Med Oncol; 2020; 12():1758835920937890. PubMed ID: 32922520
[TBL] [Abstract][Full Text] [Related]
34. Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling
Li Y; Xu C; Sun B; Zhong F; Cao M; Yang L
Front Oncol; 2022; 12():913498. PubMed ID: 35957887
[TBL] [Abstract][Full Text] [Related]
35. EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.
Pellegrino R; Calvisi DF; Neumann O; Kolluru V; Wesely J; Chen X; Wang C; Wuestefeld T; Ladu S; Elgohary N; Bermejo JL; Radlwimmer B; Zörnig M; Zender L; Dombrowski F; Evert M; Schirmacher P; Longerich T
Hepatology; 2014 May; 59(5):1886-99. PubMed ID: 24285179
[TBL] [Abstract][Full Text] [Related]
36. LncRNA TMPO-AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR-329-3p to stimulate FOXK1-mediated AKT/mTOR signaling pathway.
Guo X; Wang Y
Cancer Med; 2020 Jul; 9(14):5235-5246. PubMed ID: 32462698
[TBL] [Abstract][Full Text] [Related]
37. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
38. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
39. HIF-1/2α-Activated RNF146 Enhances the Proliferation and Glycolysis of Hepatocellular Carcinoma Cells via the PTEN/AKT/mTOR Pathway.
Shen G; Wang H; Zhu N; Lu Q; Liu J; Xu Q; Huang D
Front Cell Dev Biol; 2022; 10():893888. PubMed ID: 35721496
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of FOXO6 Inhibits Glycolysis and Reduces Cell Resistance to Paclitaxel in HCC Cells via PI3K/Akt Signaling Pathway.
Yu X; Gao X; Mao X; Shi Z; Zhu B; Xie L; Di S; Jin L
Onco Targets Ther; 2020; 13():1545-1556. PubMed ID: 32110051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
